Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
申请人:Vertex Pharmaceuticals Incorporated
公开号:US20150231142A1
公开(公告)日:2015-08-20
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
yclohexanone (A). The positions of hydroboration are established by synthesis of the hydroboration/oxidation products. The cyanidation of the organoboranes derived from myrcene and diborane leads to a 23 mixture of A and 5-(2′-hydroxyethyl)-2-isopropylcyclohexanone, the structures of which are established by independent synthesis. The hydroboration of myrcene is shown to be relatively non-stereospecific
Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties
作者:Ronald Palin、Anton Bom、John K. Clark、Louise Evans、Helen Feilden、Andrea K. Houghton、Philip S. Jones、Brian Montgomery、Mark A. Weston、Grant Wishart
DOI:10.1016/j.bmc.2006.11.030
日期:2007.2
A series of 3-phenoxypropyl piperidine benzimidazol-2-one analogues have been discovered as novel NOP receptor agonists. Structure-activity relationships have been explored via N-3 substitution of the benzimidazol-2-one with a range of functionality. The N-methyl acetamide derivative (+)-7f was found to be a high-affinity, potent NOP agonist with greater than 100-fold selectivity over the MOP receptor
Synthesis of three stereoisomers of dehydroabieticacid has been described and these together with the isomer, synthesized by Stork consitute the entire series, theoretically possible. Stereochemistry of these isomers has been placed on a firm basis.